Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities

Abstract

In a recent study published in Cancer Cell, Braun et al. introduced extracorporeal photopheresis (ECP) as a novel immunomodulatory approach to mitigate immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) without compromising anti-tumor immunity.¹ ECP suppressed Th1/Trm cell activation and neutrophil infiltration while enhancing an anti-inflammatory macrophage phenotype through adiponectin, facilitating the resolution of steroid-refractory irAEs.